Variation of amino acid sequences of serum amyloid a (SAA) and immunohistochemical analysis of amyloid a (AA) in Japanese domestic cats

Meina TEI1), Kazuyuki UCHIDA1)*, James K. CHAMBERS1), Ken-ichi WATANABE1), Takashi TAMAMOTO2), Koichi OHNO2) and Hiroyuki NAKAYAMA1)

1)Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
2)Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan

ABSTRACT. Amyloid A (AA) amyloidosis, a fatal systemic amyloid disease, occurs secondary to chronic inflammatory conditions in humans. Although persistently elevated serum amyloid A (SAA) levels are required for its pathogenesis, not all individuals with chronic inflammation necessarily develop AA amyloidosis. Furthermore, many diseases in cats are associated with the elevated production of SAA, whereas only a small number actually develop AA amyloidosis. We hypothesized that a genetic mutation in the SAA gene may strongly contribute to the pathogenesis of feline AA amyloidosis. In the present study, genomic DNA from four Japanese domestic cats (JDCs) with AA amyloidosis and from five without amyloidosis was analyzed using polymerase chain reaction (PCR) amplification and direct sequencing. We identified the novel variation combination of 45R-51A in the deduced amino acid sequences of four JDCs with amyloidosis and five without. However, there was no relationship between amino acid variations and the distribution of AA amyloid deposits, indicating that differences in SAA sequences do not contribute to the pathogenesis of AA amyloidosis. Immunohistochemical analysis using antisera against the three different parts of the feline SAA protein—i.e., the N-terminal, central, and C-terminal regions—revealed that feline AA contained the C-terminus, unlike human AA. These results indicate that the cleavage and degradation of the C-terminus are not essential for amyloid fibril formation in JDCs.

KEY WORDS: AA amyloidosis, fibril formation, Japanese domestic cat, SAA gene

Amyloid A (AA) amyloidosis is a fatal systemic condition that occurs secondary to chronic inflammatory disorders such as rheumatoid arthritis (RA) [13], tuberculosis, syphilis, chronic pyelonephritis [5], inflammatory bowel disease [24], connective tissue diseases [22], and malignancies [9, 17]. Persistently high concentrations of serum amyloid A (SAA) in the plasma are essential for the pathogenesis of AA amyloidosis [25]. Amyloid fibrils are thought to comprise partially fragmented SAA, which confers on them abnormal molecular conformations [31].

The human SAA gene has several polymorphisms. In most human cases of AA amyloidosis, SAA1, which has five alleles (SAA1.1 to 1.5), is responsible for the disease. In Caucasian patients with familial Mediterranean fever, the SAA1.1 allele has been identified as a risk factor for the development of AA amyloidosis [6]. However, Japanese patients with RA who have the SAA1.3 allele are more susceptible to AA amyloidosis [35]. Two mutation sites (Val52 and Ala57) in the deduced amino acid sequence define amyloidogenicity. The full-length human SAA, which is 104 amino acids long, is never the major species in AA amyloid proteins. The AA protein lacks the C-terminus of the SAA sequence and the main cleavage site is the 76th amino acid residue [34]. However, it has not yet been established whether the cleavage and absence of the C-terminus of SAA are essential for amyloidogenesis.

AA amyloidosis in cats also occurs secondary to chronic inflammatory conditions frequently, especially those resulting from infectious diseases [10]. Hereditary traits of AA amyloidosis have been reported in Abyssinian (Aby) and Siamese (Siam) cats [4, 32]. Three variation sites have been identified between the SAA amino acid sequences of Aby and Siam cats; these variation sites...
sites may be responsible for the differences observed in amyloidogenicity and AA deposition patterns between these breeds. AA amyloidosis also occurs sporadically in Japanese domestic cats (JDCs), and is preceded by high levels of circulating SAA; however, not all cats with the condition develop amyloidosis [28, 29]. Therefore, we hypothesize that, as in humans, genetic mutations in the SAA gene may make a large contribution to the pathogenesis of feline AA amyloidosis.

In the present study, we analyzed the genomic DNA sequences of the SAA gene in four JDCs with AA amyloidosis and five without. Our objective was to elucidate the amyloidogenic factors responsible for feline AA amyloidosis. In the present paper, we have also included a discussion of the relationship between variations in DNA sequences and the deduced amino acid sequences and patterns of AA deposition. Furthermore, we analyzed AA deposits immunohistochemically in JDCs using antisera against three different parts of the feline SAA protein, namely, the N-terminus, the central region, and the C-terminus.

**MATERIALS AND METHODS**

**Animals and tissue samples**

The cats examined in the present study are listed in Table 1. AA-laden and control liver and kidney tissues were fixed in 10\% formalin solution, routinely processed, and embedded in paraffin wax. Four-micrometer-thick paraffin sections of every organ of every case (cat Nos. 1–12) were subjected to hematoxylin and eosin (HE) and alkaline Congo red (CR) staining [21], and then subjected to immunohistochemistry and immunofluorescence analysis. The CR-stained sections were examined under a routine or polarized light microscope. The characteristic green birefringent polarization color from CR-stained tissues was regarded as proof of the presence of amyloid.

**DNA extraction and polymerase chain reaction (PCR) amplification**

Genomic DNA was extracted from fresh liver tissues from four JDCs that had been pathologically diagnosed with AA amyloidosis, and from five JDCs without amyloid deposition (Table 1) using a DNeasy® Blood and Tissue Kit (QIAGEN, Limburg, Netherlands).

Extracted DNA was subjected to PCR amplification for the feline SAA gene using PrimeSTAR® Max DNA polymerase (TaKaRa Bio, Otsu, Japan). The specific primers for exons 2, 3, and 4 of the feline SAA gene were as follows: exon 2, forward: 5′-CAA CTG CCC TCT TCC AT-3′, reverse: 5′-GAC GGA CAC AAA TCC TCT GGT-3′; exon 3, forward: 5′-CTG GAG TCG GTG GCA GAT TT-3′, reverse: 5′-CTC TGG CCC ATC AG-3′; and exon 4, forward: 5′-ACC CAG TAA GGG ATC AGC CT-3′, reverse: 5′-CAC CCC TGG GAA CGA ACA AA-3′. The PCR was performed in 50 µl of reaction fluid. The PCR regimen was: 35 cycles of a denaturation step of 98°C for 10 sec; a primer annealing step of 57°C for 5 sec; and an elongation step of 72°C for 3 sec. The PCR products were electrophoresed on an agarose gel and analyzed using a ChemiDocTM imaging system (Bio-Rad Laboratories, Hercules, CA, U.S.A.). The target amplification products were extracted from the gel bands using a QIAquick PCR purification kit (QIAGEN), and sequenced in the forward direction using the BigDye Terminator 3.1 mix (Applied Biosystems, Foster City, CA, U.S.A.) and ABI Prism 3030 Genetic Analyzer (Applied Biosystems).

**Antiserum preparation**

Antigenic peptides of the N-terminal region (MREANYIGAD), the central region (QRGPGGAWAAKV), and the C-terminal region (EWGRSGKDPNHFRP) of feline SAA were synthesized and conjugated with keyhole limpet hemocyanin (KLH). Each synthetic peptide was administered four times to three different conventional rabbits. Forty-nine days after the first administration, whole blood was collected and the antisera were obtained. The antisera were affinity-purified (Eurofins Genomics, Tokyo, Japan) (Fig. 1). The specificity of the antisera against each peptide was assessed by western blot analysis with a recombinant (rb) whole feline SAA protein and each synthetic peptide (Fig. 2). The rb feline SAA protein was produced as previously described [27].

| Cat No. | Sex | Age   | Major pathologic diagnosis at necropsy                  |
|-------|-----|-------|-------------------------------------------------------|
| 1a)   | SF  | 13 y  | Mandibular abscess and systemic AA amyloidosis         |
| 2a)   | CM  | 6 y   | Bacterial dermatitis and systemic AA amyloidosis       |
| 3a)   | CM  | 5 y 2 m| B cell lymphoma in cerebellum and systemic AA amyloidosis |
| 4a)   | SF  | 12 y 5 m| Chronic renal failure with systemic AA amyloidosis    |
| 5     | CM  | 2 y 2 m| Osteochondromatosis and systemic AA amyloidosis.       |
| 6     | SF  | 9 y 8 m| Intestinal lymphoma (small cell type) and systemic AA amyloidosis |
| 7     | SF  | 15 y  | Pyogenic bronchitis, interstitial pneumonia, acute myocarditis and systemic AA amyloidosis |
| 8a)   | SF  | 13 y 3 m| Systemic metastasis of mammary gland carcinoma       |
| 9a)   | SF  | 16 y  | Systemic metastasis of anaplastic plasmacytoma        |
| 10a)  | CM  | 12 y 2 m| Systemic histiocytosis                                 |
| 11a)  | F   | 15 y  | Systemic metastasis of mammary gland carcinoma        |
| 12a)  | M   | 10 y  | Systemic metastasis of T cell lymphoma                |

Table 1. JDC cats examined in the present study

a) Cats subjected to the DNA sequence analysis. SF, Spayed female; CM, Castrated male; F, Female; M, Male; AA, amyloid A.
Immunohistochemistry and immunofluorescence

An immunohistochemical analysis was performed using an Envision polymer system (Dako, Kyoto, Japan). Deparaffinized sections were incubated with 0.1% actinase E at room temperature for 10 min for the reaction with the anti-AA mouse monoclonal antibody. Endogenous peroxidase activity in the sections was blocked with 3% hydrogen peroxide/methanol at room temperature for 5 min. The sections were incubated in 8% skimmed milk/Tris-buffered saline (TBS) at 37°C for 40 min to avoid non-specific reactions. The sections were then incubated at 4°C overnight with the primary antibodies listed in Table 2, respectively. After washing three times in TBS, the sections were incubated with Envision horseradish peroxidase-labeled polymer anti-mouse or anti-rabbit IgG (Dako) at 37°C for 40 min. The sections were washed with TBS and the reaction products were visualized with 0.05% 3,3′-diaminobenzidine and 0.03% hydrogen peroxide in TBS. Counterstaining was performed with Mayer’s hematoxylin. Corresponding slides are incubated with TBS in place of the primary antibody, as negative controls.

Four-micrometer-thick paraffin tissue sections were treated with 8% skimmed milk in Tris-buffered saline with 0.1% Tween 20 (TBST) at 37°C for 40 min to avoid non-specific reactions. The sections were then incubated with antisera raised to the synthetic SAA peptides (AS-Nos. 1, 2 and 3) (Table 2) at 4°C overnight. After washing, the sections were incubated with a secondary antibody (Alexa Fluor 488 goat anti-rabbit IgG, 1:100 dilution, Life Technologies, Carlsbad, CA, U.S.A.) at 37°C for 60 min. The reactions were visualized with 4′,6-diamidino-2-phenylindole (DAPI) and observed with a fluorescence microscope. As described in the Immunohistochemistry and immunofluorescence section, the sections were incubated with TBS in place of the primary antibody, as negative controls.

Table 2. Primary antibodies used for Immunohistochemistry, Immunofluorescence and Western blot analysis

| Antibody       | Antigen   | Species | Dilution | Supplier               |
|---------------|-----------|---------|----------|------------------------|
| AA (clone KM268) | Human SAA 37–47 | Mouse   | 1:50 (IF) | Kyowa Medics          |
| AS-No.1       | Cat SAA 23–32 | Rabbit  | 1:150 (IF) | Eurofins Genomics     |
|               |           |         | 1:1,000 (WB) |                        |
| AS-No.2       | Cat SAA 45–56 | Rabbit  | 1:150 (IF) | Eurofins Genomics     |
|               |           |         | 1:1,000 (WB) |                        |
| AS-No.3       | Cat SAA 91–104 | Rabbit  | 1:150 (IF) | Eurofins Genomics     |
|               |           |         | 1:1,000 (WB) |                        |

Immunohistochemistry and immunofluorescence

An immunohistochemical analysis was performed using an Envision polymer system (Dako, Kyoto, Japan). Deparaffinized sections were incubated with 0.1% actinase E at room temperature for 10 min for the reaction with the anti-AA mouse monoclonal antibody. Endogenous peroxidase activity in the sections was blocked with 3% hydrogen peroxide/methanol at room temperature for 5 min. The sections were incubated in 8% skimmed milk/Tris-buffered saline (TBS) at 37°C for 40 min to avoid non-specific reactions. The sections were then incubated at 4°C overnight with the primary antibodies listed in Table 2, respectively. After washing three times in TBS, the sections were incubated with Envision horseradish peroxidase-labeled polymer anti-mouse or anti-rabbit IgG (Dako) at 37°C for 40 min. The sections were washed with TBS and the reaction products were visualized with 0.05% 3,3′-diaminobenzidine and 0.03% hydrogen peroxide in TBS. Counterstaining was performed with Mayer’s hematoxylin. Corresponding slides are incubated with TBS in place of the primary antibody, as negative controls.

Four-micrometer-thick paraffin tissue sections were treated with 8% skimmed milk in Tris-buffered saline with 0.1% Tween 20 (TBST) at 37°C for 40 min to avoid non-specific reactions. The sections were then incubated with antisera raised to the synthetic SAA peptides (AS-Nos. 1, 2 and 3) (Table 2) at 4°C overnight. After washing, the sections were incubated with a secondary antibody (Alexa Fluor 488 goat anti-rabbit IgG, 1:100 dilution, Life Technologies, Carlsbad, CA, U.S.A.) at 37°C for 60 min. The reactions were visualized with 4′,6-diamidino-2-phenylindole (DAPI) and observed with a fluorescence microscope. As described in the Immunohistochemistry and immunofluorescence section, the sections were incubated with TBS in place of the primary antibody, as negative controls.

doi: 10.1292/jvms.17-0447
sections were then incubated in a 1% CR solution for 10 min, and washed in a saturated lithium carbonate solution. To break non-specific bonds, the sections were incubated in 80% ethanol for 5 min. The sections were finally mounted using VECTASHIELD HardSet medium with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, U.S.A.), and examined using a Carl Zeiss LSM700 confocal laser microscope (Carl Zeiss Micro Imaging, Tokyo, Japan) equipped with a red filter with an excitation peak of 596 nm and an emission maximum of 620 nm. Corresponding slides were incubated with TBS or TBST in place of the primary antibody or antisera, as negative controls.

RESULTS

Histopathology

Table 3 shows the tissue distribution and severity of AA deposition in the cats examined. Amyloid deposits were immunopositive for AA in all cats. Four (Nos. 1–3 and 5) out of seven cats with systemic AA amyloidosis exhibited severe deposition of AA in the liver, whereas two (Nos. 6 and 7) showed moderate deposition. AA was located in the vessel wall of the Glisson’s capsule, around the central veins, and in the space of Disse along the sinusoids adjacent to the cords of hepatocytes (Fig. 3a–c). In the areas with severe AA deposition, the remaining hepatocytes showed atrophic changes. Cats with moderate to severe AA deposition in the renal glomeruli also showed minimal to mild deposition in the medullary interstitium (Nos. 1 and 3), whereas the opposite was noted in the others (Nos. 4 and 6). Glomerular amyloid was detected segmentally in the mesangial region (Fig. 4a–c). In cat No. 4, AA deposition was not detected in the liver, but was prominent in the renal medulla (Fig. 5a–c). Furthermore, the thyroid gland, intestines, adrenal gland, and tongue were the favored sites of AA deposition. In the thyroid gland, AA was deposited in the interfollicular interstitium and accompanied by follicular atrophy (Fig. 6a–c). In the intestines, AA was mainly detected in the lamina propria.

SAA protein sequence of JDCs

The nucleotide sequence of the feline SAA gene was determined for exons 2–4, with liver samples from nine cats (Nos. 1–4; AA amyloidosis, Nos. 8–12; non-amyloidosis controls) by a direct sequencing method, and the deduced amino acid sequences of the SAA protein were compared with that of Aby cats, which is registered, and Siam cats [16, 20] (Table 4). Three variation sites were found at positions 1, 45 and 51. All control (Nos. 8–12) and two amyloidosis (Nos. 1–4) cats had the same amino acid combination of 45R and 51A, whereas No. 2 had the same amino acids at the same positions as those of the previous Aby case. The kidney was the main target organ in the Aby case of amyloidosis, whereas severe AA deposition was also observed in the liver of No. 2. Although no present JDC cases showed the same sequences at positions 45 and 51 with the previous Siam case, in which the liver was the main target organ, three out of four of the present JDC amyloid cases (Nos. 1–3) exhibited severe AA deposition in the liver. There was an absence of patterns between variations at position 1 and the incidence of AA amyloidosis or deposition patterns.

Immunohistochemistry and immunofluorescence

Antisera of Nos. 1–3 were prepared against residues 23–32, 45–56 and 91–104 of feline SAA, respectively, (Fig. 1). Each antiserum was immunoreacted with rb feline total SAA as well as the corresponding immunogen peptides (Fig. 2). The results of the immunohistochemical analysis demonstrated that CR-positive AA deposits in the liver and kidney were recognized by antisera raised to the peptides within the feline SAA protein (Figs. 7–9). These results indicate that, in contrast to humans, the feline AA protein contains the amino acid residues 23–104 of SAA, suggesting that the cleavage and metabolism of the C-terminal sequence are not essential elements in the formation of amyloid fibrils.

DISCUSSION

We herein identified three amino acid variations at positions 1, 45 and 51 in the feline SAA protein. The common combination
Fig. 3. Amyloid A (AA) amyloidosis, Liver, Cat No. 1, AA deposited around the central vein and in the space of Disse. Hematoxylin and eosin (HE) (a), alkaline Congo red (CR) (b) and CR with a polarized light (c). Bar, 50 µm.

Fig. 4. Amyloid A (AA) amyloidosis, Kidney, Cat No. 6, AA deposited segmentally in the renal glomerulus. Hematoxylin and eosin (HE) (a), alkaline Congo red (CR) (b) and CR with a polarized light (c). Bar, 25 µm.

Fig. 5. Amyloid A (AA) amyloidosis, Kidney, Cat No. 4, AA deposited in the interstitium of the medulla. Hematoxylin and eosin (HE) (a), alkaline Congo red (CR) (b) and CR with a polarized light (c). Bar, 50 µm.

Fig. 6. Amyloid A (AA) amyloidosis, Thyroid gland, Cat, No. 6, AA deposited in the interfollicular interstitium. Hematoxylin and eosin (HE) (a), alkaline Congo red (CR) (b) and CR with a polarized light (c). Bar, 25 µm.
of 45R-51A found in the JDCs has not been reported in any other mammalian species, but has been reported in chickens (Table 5). AA amyloidosis in chickens is often observed as amyloid arthropathy accompanied by Enterococcus faecalis infection, although its incidence is low [26]. Although researchers have investigated the amino acid sequence of the SAA protein and its amyloidogenicity in cats [11, 16], variations related to the onset of amyloidogenesis were not identified. The results of the present study were not sufficient to determine whether the amino acid combination of 45R-51A produces amyloids.

The native conformation of human SAA1.1 has recently been elucidated, and positions 45 and 51 are included in two different alpha helix moieties [15]. Previous studies [14, 33] have suggested that the N-terminal residue of human SAA1.1 is involved in amyloidogenicity. Furthermore, according to a study by Lu et al. [15], residues 1–7 and 51–58 were confirmed to be amyloidogenic. Therefore, the 51A-V variation in JDCs may be related to the amyloidogenicity of feline SAA. Further studies are needed on the amyloidogenicity of the feline SAA peptide.

Familial AA amyloidosis in Aby cats is clinically and histopathologically similar to familial Mediterranean fever (FMF) in humans [8]. The gene responsible for FMF is MEFV, not SAA, and it encodes a protein called pyrin [18]. MEFV has not yet been investigated in cats. Mutations in the MEFV gene result in the aberrant functioning of pyrin leading to autoinflammation. The authors of a previous study [16] on familial AA amyloidosis in Aby and Siam cats proposed a relationship between the sequence of feline SAA amino acid residues and target organs. However, we are currently unable to confirm the relationship between amino acid sequence variations and the tissue predilection of AA amyloid deposition in JDCs. Persistently high serum levels of SAA are essential for the development of AA amyloidosis in humans [3]. In feline AA amyloidosis, which was examined in the present study, the distribution of AA amyloid deposits appears to depend on the duration and severity of inflammation, but not on the amino acid sequence of the SAA protein. The involvement of other candidate factors in the pathogenesis of AA amyloidosis, including the MEFV gene and chaperone proteins such as ApoE, the serum amyloid P component, and glycosaminoglycan, remains unclear [1, 12, 30].

Another possible factor that influences the pathology of AA amyloidosis is the cleavage of the SAA protein. The human AA protein has been analyzed by mass spectrometry and was found to consist of 76 residues from the N-terminus of SAA [23]. The proteolysis of SAA has been proposed as the trigger for amyloidogenesis. The authors of a previous study [16] reported that feline AA also consists of an N-terminal fragment of SAA, but the involvement of the C-terminus in AA remains obscure. Furthermore, in the present study the immunohistochemical investigations showed that feline AA contains the N-terminus (23–32), the central region (32–56), and the C-terminus (91–104) of feline SAA. These results suggest that, in common with the AA of humans and other mammals, feline AA amyloid contains the C-terminal fragment of SAA. Previous findings [16] were obtained using the Edman degeneration method with a protein sequencer. In this method, sequencing proceeds from the N-terminus and stops when a chemically modified amino acid residue is encountered. Therefore, difficulties are associated with analyzing C-terminal residues using this method [2]. This may be one reason for the obscure sequence of the feline AA protein. Patke et al. [19] previously reported that the truncation of the C-terminus of murine SAA significantly reduced its rate of fibrillation in vitro, suggesting that the C-terminus plays a certain kinetic role in SAA fibril formation, which is consistent with the results of the present study.

We herein demonstrated that JDCs have three amino acid variation sites in the SAA gene. One of the variations is novel among mammals; however, the involvement of these variations in AA fibril formation remains unclear. Unlike human AA, JDC AA contains the C-terminal residues of feline SAA, suggesting that the cleavage and degradation of the C-terminus is not necessary for the formation of amyloid fibrils.

ACKNOWLEDGMENTS. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Grant-in-Aid for Science Research from the Japan Society for the Promotion of Science (KAKENHI 13J07770).
Fig. 7. Amyloid A (AA) amyloidosis, Liver, Cat No. 5, AA deposited mainly in the space of Disse. Alkaline Congo red (CR) (a), and immunostained with AS-No. 1 (b), AS-No. 2 (c), and AS-No. 3 (d). Bar, 50 µm.

Fig. 8. Amyloid A (AA) amyloidosis, Kidney, Cat No. 6, AA deposited in the glomerulus and in the walls of arterioles. Alkaline Congo red (CR) (a), and immunostained with AS-No. 1 (b), AS-No. 2 (c), and AS-No. 3 (d). Bar, 25 µm.

Fig. 9. Amyloid A (AA) amyloidosis, Liver, Cat No. 5, Alkaline Congo red (CR)-stained liver sections examined with a confocal laser microscope (a, d and g), and those immunostained with AS-No. 1 (b), No. 2 (e), and No. 3 (h). CR-positive AA deposits also immunoreacted with AS-No. 1 (c), AS-No. 2 (f), and AS-No. 3 (i). Bar, 50 µm.
Table 5. Amino acid sequence of the SAA protein from various species

| Amino acid sequence | 45 | 51 |
|---------------------|--|--|
| Human               | R G N Y D A A | K R G P G G | V W A A E A I S D A R E |
| Mouse               | R G N Y D A A | Q R G P G G | V W A A E K I S D A R E |
| Cat (Aby)           | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Cat (Siam)          | R G N Y D A A | R R G P G G | A W A A K V I S D A R E |
| Cat (JDC)           | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Chicken             | R G N Y D A A | R R G P G G | A W A A K V I S D A R E |
| Cow                 | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Dog                 | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Mink                | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Pig                 | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Rabbit              | R G N Y D A A | Q R G P G G | V W A A K V I S D A R E |

The sequences were aligned based on human SAA on Uniprot.

REFERENCES

1. Aguilera, J. J., Zhang, F., Beaudet, J. M., Linhardt, R. J. and Colón, W. 2014. Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A. Biochimie 104: 70–80. [Medline] [CrossRef]
2. Bailey, J. M. 1995. Chemical methods of protein sequence analysis. J. Chromatogr. A 705: 47–65. [Medline] [CrossRef]
3. Benson, M. D. and Cohen, A. S. 1979. Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases. Arthritis Rheum. 22: 36–42. [Medline] [CrossRef]
4. Boyce, J. T., DiBartola, S. P., Chew, D. J. and Gasper, P. W. 1984. Familial renal amyloidosis in Abyssinian cats. Vet. Pathol. 21: 33–38. [Medline] [CrossRef]
5. Brownstein, M. H. and Helwig, E. B. 1971. Secondary systemic amyloidosis: an analysis of underlying disorders. South. Med. J. 64: 491–496. [Medline] [CrossRef]
6. Cazeneuve, C., Ajrapetyan, H., Papin, S., Roudot-Thoraval, F., Geneviève, D., Mndjoyan, E., Papazian, M., Sarkisian, A., Babloyian, A., Boissier, B., Duquesnoy, P., Kouyoumdjian, J. C., Girondon-Boulandet, E., Grateau, G., Sarkisian, T. and Amselem, S. 2000. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am. J. Hum. Genet. 67: 1136–1143. [Medline] [CrossRef]
7. Clement, C. G. and Truong, L. D. 2014. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis. Hum. Pathol. 45: 1766–1772. [Medline] [CrossRef]
8. DiBartola, S. P., Benson, M. D., Dwulet, F. E. and Carnacoff, J. B. 1985. Isolation and characterization of amyloid protein AA in the Abyssinian cat. Lab. Invest. 52: 485–489. [Medline] [CrossRef]
9. Garthwaite, E. A., Sellars, L. and Bhandari, S. 2003. Carcinoma of the bronchus presenting as renal failure secondary to amyloidosis. Nephrol. Dial. Transplant. 18: 1031. [Medline] [CrossRef]
10. Johnson, K. H., Westermarck, P., Sletten, K. and Obrien, T. D. 1996. Amyloid proteins and amyloidosis in domestic animals. Amyloid-International Journal of Experimental and Clinical Investigation. 3: 270–289. [CrossRef]
11. Johnson, K. H., Sletten, K., Werdin, R. E., Westermarck, G. T., O’Brien, T. D. and Westermarck, P. 1989. Amino acid sequence variations in protein AA of cats with high and low incidences of AA amyloidosis. Comp. Biochem. Physiol. B 94: 765–768. [Medline] [CrossRef]
12. Kidy, M. S., King, A. R., Perry, G., de Beer, M. C. and de Beer, F. C. 1995. Association of apolipoprotein E with murine amyloid A protein amyloid. Lab. Invest. 73: 469–475. [Medline] [CrossRef]
13. Kobayashi, H., Tada, S., Fuchigami, T., Okuda, Y., Takasugi, K., Matsumoto, T., Iida, M., Aoyagi, K., Iwashita, A., Daimaru, Y. and Fujishima, M. 1996. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br. J. Rheumatol. 35: 44–49. [Medline] [CrossRef]
14. Liu, Y., Cui, D., Hoshii, Y., Kawano, H., Uno, Y., Gondo, T. and Ishihara, T. 2007. Induction of murine AA amyloidosis by various homogeneous amyloid fibrils and amyloid-like synthetic peptides. Scand. J. Immunol. 66: 495–500. [Medline] [CrossRef]
15. Lu, J., Yu, Y., Zhu, I., Cheng, Y. and Sun, P. D. 2014. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 111: 5189–5194. [Medline] [CrossRef]
16. Niewold, T. A., van der Linde-Sipman, J. S., Murphy, C., Tooten, P. C. and Gruys, E. 1999. Familial amyloidosis in cats: Siamese and Abyssinian AA proteins differ in primary sequence and pattern of deposition. Amyloid 6: 205–209. [Medline] [CrossRef]
17. Nobata, H., Saga, N., Itoh, A., Miura, N., Kitagawa, W., Morita, H., Yokoi, T., Banno, S. and Imai, H. 2012. Systemic AA amyloidosis in a patient with lung metastasis from renal cell carcinoma. Amyloid 19: 197–200. [Medline] [CrossRef]
18. Onen, F. 2006. Familial Mediterranean fever. Rheumatol. Int. 26: 489–496. [Medline] [CrossRef]
19. Patke, S., Maheshwari, R., Litt, J., Srinivasan, S., Aguilera, J. J., Colón, W. and Kane, R. S. 2012. Influence of the carboxy terminus of serum amyloid A on protein oligomerization, misfolding, and fibril formation. Biochemistry 51: 3092–3099. [Medline] [CrossRef]
20. Pontius, J. U., Mullikin, J. C., Smith, D. R., Lindblad-Toh, K., Gnerre, S., Clamp, M., Chang, J., Stephens, R., Neelam, B., Volfovy, N., Schäffer, A. A., Agarwala, R., Narfström, K., Murphy, W. J., Giger, U., Roca, A. L., Antunes, A., Menotti-Raymond, M., Yukhi, N., Pecon-Slattery, J., Johnson, W. E., Bourque, G., Tesler, G., O’Brien, S. J., Program, N. C. S., O’Brien S. J., Agencourt Sequencing Team NISC Comparative Sequencing Program. 2007. Initial sequence and comparative analysis of the cat genome. Genome Res. 17: 1675–1689. [Medline] [CrossRef]
21. Puchtler, H., Sweat, F. and Levine, M. 1962. On the binding of Congo red by amyloid. Journal of histochemistry and biochemistry 3: 270–289. [CrossRef]
22. Rajagopala, S., Singh, N., Gupta, K. and Gupta, D. 2010. Pulmonary amyloidosis in Sjogren’s syndrome: a case report and systematic review of the literature. Respir. Med. 104: 355–364. [Medline] [CrossRef]
23. Rücken, C., Menard, R., Bühling, F., Vöckler, S., Raynes, J., Stix, B., Krüger, S., Roessner, A. and Kähne, T. 2005. Proteolysis of serum amyloid

Table 5.

| Amino acid sequence | 45 | 51 |
|---------------------|--|--|
| Human               | R G N Y D A A | K R G P G G | V W A A E A I S D A R E |
| Mouse               | R G N Y D A A | Q R G P G G | V W A A E K I S D A R E |
| Cat (Aby)           | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Cat (Siam)          | R G N Y D A A | R R G P G G | A W A A K V I S D A R E |
| Cat (JDC)           | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Chicken             | R G N Y D A A | R R G P G G | A W A A K V I S D A R E |
| Cow                 | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Dog                 | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Mink                | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Pig                 | R G N Y D A A | Q R G P G G | A W A A K V I S D A R E |
| Rabbit              | R G N Y D A A | Q R G P G G | V W A A K V I S D A R E |

The sequences were aligned based on human SAA on Uniprot.
A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. *Ann. Rheum. Dis.* **64**: 808–815. [Medline] [CrossRef]

24. Sattianayagam, P. T., Gillmore, J. D., Pinney, J. H., Gibbs, S. D., Wechalekar, A. D., Gilbertson, J. A., Rowcezenio, D., Hawkins, P. N. and Lachmann, H. J. 2013. Inflammatory bowel disease and systemic AA amyloidosis. *Dig. Dis. Sci.* **58**: 1689–1697. [Medline] [CrossRef]

25. Simons, J. P., Al-Shawi, R., Ellmerich, S., Speck, I., Aslam, S., Hutchinson, W. L., Mangione, P. P., Disterer, P., Gilbertson, J. A., Hunt, T., Millar, D. J., Minogue, S., Bodin, K., Pepys, M. B. and Hawkins, P. N. 2013. Pathogenetic mechanisms of amyloid A amyloidosis. *Proc. Natl. Acad. Sci. U.S.A.* **110**: 16115–16120. [Medline] [CrossRef]

26. Steentjes, A., Veldman, K. T., Mevius, D. J. and Landman, W. J. M. 2002. Molecular epidemiology of unilateral amyloid arthropathy in broiler breeders associated with *Enterococcus faecalis*. *Avian Pathol.* **31**: 31–39. [Medline] [CrossRef]

27. Tamamoto, T., Ohno, K., Goto-Koshino, Y., Fujino, Y. and Tsujimoto, H. 2012. Serum amyloid A uptake by feline peripheral macrophages. *Vet. Immunol. Immunopathol.* **150**: 47–52. [Medline] [CrossRef]

28. Tamamoto, T., Ohno, K., Ohmi, A., Seki, I. and Tsujimoto, H. 2009. Time-course monitoring of serum amyloid A in a cat with pancreatitis. *Vet. Clin. Pathol.* **38**: 83–86. [Medline] [CrossRef]

29. Tamamoto, T., Ohno, K., Takahashi, M., Nakashima, K., Fujino, Y. and Tsujimoto, H. 2013. Serum amyloid A as a prognostic marker in cats with various diseases. *J. Vet. Diagn. Invest.* **25**: 428–432. [Medline] [CrossRef]

30. Togashi, S., Lim, S. K., Kawano, H., Ito, S., Ishihara, T., Okada, Y., Nakano, S., Kinoshita, T., Horie, K., Episkopou, V., Gottesman, M. E., Costantini, F., Shimada, K. and Maeda, S. 1997. Serum amyloid P component enhances induction of murine amyloidosis. *Lab. Invest.* **77**: 525–531. [Medline]

31. van der Hilst, J. C. H. 2011. Recent insights into the pathogenesis of type AA amyloidosis. *ScientificWorldJournal* **11**: 641–650. [Medline] [CrossRef]

32. van der Linde-Sipman, J. S., Niewold, T. A., Tooten, P. C. J., de Neijs-Backer, M. and Gruys, E. 1997. Generalized AA-amyloidosis in Siamese and Oriental cats. *Vet. Immunol. Immunopathol.* **56**: 1–10. [Medline] [CrossRef]

33. Westermark, G. T., Engström, U. and Westermark, P. 1992. The N-terminal segment of protein AA determines its fibrillogenic property. *Biochem. Biophys. Res. Commun.* **182**: 27–33. [Medline] [CrossRef]

34. Yamada, T., Liepnies, J. J., Kluve-Beckerman, B. and Benson, M. D. 1995. Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. *Scand. J. Immunol.* **41**: 94–97. [Medline] [CrossRef]

35. Yamada, T., Okuda, Y., Takasugi, K., Wang, L., Marks, D., Benson, M. D. and Kluve-Beckerman, B. 2003. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. *Amyloid* **10**: 7–11. [Medline] [CrossRef]